This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Canonico, M. Search for Related Content PubMed PubMed Citation Articles by Canonico, M. Related Collections Deep vein thrombosis Epidemiology

(Circulation. 2007;115:840-845.)
© 2007 American Heart Association, Inc.

Cardiovascular Disease in Women

Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women

Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study

Marianne Canonico, PhD; Emmanuel Oger, MD, PhD; Geneviève Plu-Bureau, MD, PhD; Jacqueline Conard, PhD; Guy Meyer, MD; Hervé Lévesque, MD; Nathalie Trillot, MD; Marie-Thérèse Barrellier, MD; Denis Wahl, MD, PhD; Joseph Emmerich, MD, PhD; Pierre-Yves Scarabin, MD, MSc, for the Estrogen and Thromboembolism Risk (ESTHER) Study Group

From Inserm Unit 780, Cardiovascular Epidemiology Section, Villejuif (M.C., E.O., G.P.-B., P.-Y.S.); Université Paris-Sud 11, Villejuif (M.C., E.O., P.-Y.S.); Département de Médecine Interne, GETBO, Hôpital de la Cavale Blanche, Brest (E.O.); Université Paris 5 Réné Descartes, Service d’Hématologie Biologique, Hôpital Hôtel-Dieu, Paris (G.P.-B., J.C.); Université Paris-Descartes, Faculté de Médecine; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris (G.M.); Département de Médecine Interne, CHU Rouen, Rouen (H.L.); Institut d’Hématologie-Transfusion, CHUR, Lille (N.T.); Service d’Explorations Fonctionnelles, CHU Côte de Nacre, Caen (M.-T.B.); Unité de Médecine Interne Thrombose Maladies Vasculaires, CHU Nancy, Hôpital de Brabois, and INSERM U734, Faculté de Médecine de Nancy-Université Henri Poincaré, Vandoeuvre-Les-Nancy (D.W.); and Université Paris Descartes, Inserm U428 and Service de Médecine Vasculaire-HTA, Hôpital Européen Georges Pompidou, Paris (J.E.), France.

Correspondence to P.Y. Scarabin, Inserm Unit 780, Cardiovascular Epidemiology Section, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France. E-mail scarabin{at}vjf.inserm.fr

Received May 26, 2006; accepted November 8, 2006.

Background— Oral estrogen therapy increases the risk of venous thromboembolism (VTE) in postmenopausal women. Transdermal estrogen may be safer. However, currently available data have limited the ability to investigate the wide variety of types of progestogen.

Methods and Results— We performed a multicenter case–control study of VTE among postmenopausal women 45 to 70 years of age between 1999 and 2005 in France. We recruited 271 consecutive cases with a first documented episode of idiopathic VTE (208 hospital cases, 63 outpatient cases) and 610 controls (426 hospital controls, 184 community controls) matched for center, age, and admission date. After adjustment for potential confounding factors, odds ratios (ORs) for VTE in current users of oral and transdermal estrogen compared with nonusers were 4.2 (95% CI, 1.5 to 11.6) and 0.9 (95% CI, 0.4 to 2.1), respectively. There was no significant association of VTE with micronized progesterone and pregnane derivatives (OR, 0.7; 95% CI, 0.3 to 1.9 and OR, 0.9; 95% CI, 0.4 to 2.3, respectively). In contrast, norpregnane derivatives were associated with a 4-fold-increased VTE risk (OR, 3.9; 95% CI, 1.5 to 10.0).

Conclusions— Oral but not transdermal estrogen is associated with an increased VTE risk. In addition, our data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect to thrombotic risk. If confirmed, these findings could benefit women in the management of their menopausal symptoms with respect to the VTE risk associated with oral estrogen and use of progestogens.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				R. L. Barbieri Update in Female Reproduction: A Life-Cycle Approach J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2439 - 2446. [Abstract] [Full Text] [PDF]

				J. E. Buster, W. D. Koltun, M. L. G. Pascual, W. W. Day, and C. Peterson Low-Dose Estradiol Spray to Treat Vasomotor Symptoms: A Randomized Controlled Trial Obstet. Gynecol., June 1, 2008; 111(6): 1343 - 1351. [Abstract] [Full Text] [PDF]

				H. Roberts Type of hormone replacement therapy and risk of venous thromboembolism BMJ, May 31, 2008; 336(7655): 1203 - 1204. [Full Text] [PDF]

				J. L. Shifren, N. Rifai, S. Desindes, M. McIlwain, G. Doros, and N. A. Mazer A Comparison of the Short-Term Effects of Oral Conjugated Equine Estrogens Versus Transdermal Estradiol on C-Reactive Protein, Other Serum Markers of Inflammation, and Other Hepatic Proteins in Naturally Menopausal Women J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1702 - 1710. [Abstract] [Full Text] [PDF]

				M. M. Sellers and J. N. Stallone Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H1978 - H1986. [Abstract] [Full Text] [PDF]

				K. D. Yi, Z. Y. Cai, D. F. Covey, and J. W. Simpkins Estrogen Receptor-Independent Neuroprotection via Protein Phosphatase Preservation and Attenuation of Persistent Extracellular Signal-Regulated Kinase 1/2 Activation J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1188 - 1195. [Abstract] [Full Text] [PDF]

				C. Vitale, G. Mercuro, E. Cerquetani, G. Marazzi, R. Patrizi, F. Pelliccia, M. Volterrani, M. Fini, P. Collins, and G. M.C. Rosano Time Since Menopause Influences the Acute and Chronic Effect of Estrogens on Endothelial Function Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 348 - 352. [Abstract] [Full Text] [PDF]

				Low-Dose Transdermal Estrogens Obstet. Gynecol., January 1, 2008; 111(1): 209 - 211. [Full Text] [PDF]

				M.-C. Micheletti and T. Chevallier Letter by Micheletti and Chevallier Regarding Article, "Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study" Circulation, September 25, 2007; 116(13): e362 - e362. [Full Text] [PDF]

				M. Canonico, E. Oger, G. Plu-Bureau, P.-Y. Scarabin, J. Conard, G. Meyer, H. Levesque, N. Trillot, M.-T. Barrellier, D. Wahl, et al. Response to Letter Regarding Article, "Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study" Circulation, September 25, 2007; 116(13): e363 - e363. [Full Text] [PDF]

				E. A. Booth and B. R. Lucchesi Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17beta-estradiol in an in vivo model of myocardial ischemia and reperfusion Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1408 - H1415. [Abstract] [Full Text] [PDF]

				C.S. Vieira, R.A. Ferriani, A.A. Garcia, M.C. Pintao, G.D. Azevedo, M.K.O. Gomes, and M.F. Silva-de-Sa Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade Hum. Reprod., August 1, 2007; 22(8): 2196 - 2201. [Abstract] [Full Text] [PDF]

				E. Haas, M. R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H. H. Nguyen, A. Heigl, M. Lachat, M. Genoni, and M. Barton Differential Effects of 17{beta}-Estradiol on Function and Expression of Estrogen Receptor {alpha}, Estrogen Receptor {beta}, and GPR30 in Arteries and Veins of Patients With Atherosclerosis Hypertension, June 1, 2007; 49(6): 1358 - 1363. [Abstract] [Full Text] [PDF]

				Menopausal Hormone Therapy and Blood Clots: Is It All in the Delivery? Journal Watch Women's Health, April 5, 2007; 2007(405): 2 - 2. [Full Text]

				K. M. Rexrode and J. E. Manson Are Some Types of Hormone Therapy Safer Than Others?: Lessons From the Estrogen and Thromboembolism Risk Study Circulation, February 20, 2007; 115(7): 820 - 822. [Full Text] [PDF]